



International Science Group

ISG-KONF.COM

VIII

**INTERNATIONAL SCIENTIFIC
AND PRACTICAL CONFERENCE
"PRIORITY AREAS OF RESEARCH IN THE SCIENTIFIC
ACTIVITY OF TEACHERS"**

Zagreb, Croatia

February 27 – March 01, 2024

ISBN 979-8-89292-749-9

DOI 10.46299/ISG.2024.1.8

UDC 01.1

The 8th International scientific and practical conference “Priority areas of research in the scientific activity of teachers” (February 27 – March 01, 2024) Zagreb, Croatia. International Science Group. 2024. 298 p.

ISBN – 979-8-89292-749-9

DOI – 10.46299/ISG.2024.1.8

EDITORIAL BOARD

<u>Pluzhnik Elena</u>	Professor of the Department of Criminal Law and Criminology Odessa State University of Internal Affairs Candidate of Law, Associate Professor
<u>Liudmyla Polyvana</u>	Department of Accounting and Auditing Kharkiv National Technical University of Agriculture named after Petr Vasilenko, Ukraine
<u>Mushenyk Iryna</u>	Candidate of Economic Sciences, Associate Professor of Mathematical Disciplines, Informatics and Modeling. Podolsk State Agrarian Technical University
<u>Prudka Liudmyla</u>	Odessa State University of Internal Affairs, Associate Professor of Criminology and Psychology Department
<u>Marchenko Dmytro</u>	PhD, Associate Professor, Lecturer, Deputy Dean on Academic Affairs Faculty of Engineering and Energy
<u>Harchenko Roman</u>	Candidate of Technical Sciences, specialty 05.22.20 - operation and repair of vehicles.
<u>Belei Svitlana</u>	Ph.D., Associate Professor, Department of Economics and Security of Enterprise
<u>Lidiya Parashchuk</u>	PhD in specialty 05.17.11 "Technology of refractory non-metallic materials"
<u>Levon Mariia</u>	Candidate of Medical Sciences, Associate Professor, Scientific direction - morphology of the human digestive system
<u>Hubal Halyna Mykolaiivna</u>	Ph.D. in Physical and Mathematical Sciences, Associate Professor

9.	Бугайчук К.Л. ОКРЕМІ ПИТАННЯ ОРГАНІЗАЦІЇ ТА ПРОВЕДЕННЯ АКРЕДИТАЦІЙНОГО ПРОЦЕСУ У ЗВО СИСТЕМИ МВС УКРАЇНИ	68
10.	Приварський Ю.Ю. ВЗАЄМОДІЯ ОРГАНІВ МІСЦЕВОГО САМОВРЯДУВАННЯ ТА ПРАВООХОРОННИХ ОРГАНІВ В УМОВАХ ВОЄННОГО СТАНУ	72
MEDICINE		
11.	Rusnak I., Kornivskyi B. NUTRITION, GIVING HEALTH TO THE CARDIOVASCULAR SYSTEM.LITERATURE REVIEW	77
12.	Serheta I. FEATURES OF THE USE OF TEST TASKS CONTROL DURING THE TEACHING OF THE ACADEMIC DISCIPLINE “HYGIENE AND ECOLOGY”	82
13.	Siusiuka V., Serhienko M., Demidenko O., Shevchenko A., Kyryliuk O. MANAGEMENT OF MENOPAUSAL OSTEOPOROSIS	84
14.	Symonenko R., Martynuk I. ANALYSIS OF THE ANTIMICROBIAL ACTION OF BACTERIA BACILLUS LICHENIFORMIS IN RELATION TO THE MICROFLORA OF PERIODONTAL POCKETS	87
15.	Кеч Н.Р., Чайковська Г.С., Осадчук З.В., Петріца Н.А., Дробчак М.І. КЛІНІЧНІ ВАРІАНТИ ПЕРЕБІГУ ПОСТКОВІДНОГО СИНДРОМУ У ДІТЕЙ	89
16.	Красовська А.О., Куліш А.В., РОЛЬ КЛІТИН ВРОДЖЕНОГО ІМУНІТЕТУ В РОЗВИТКУ АНЕВРИЗМИ ЧЕРЕВНОЇ АОРТИ	95
17.	Нечитайло Л.Я., Ощипко Т.В., Сердюченко Ю.С., Рогова В.В., Падюка А.А.	98

MANAGEMENT OF MENOPAUSAL OSTEOPOROSIS

Siusiuka Volodymyr

MD, PhD, DSc. Professor of the Department of Obstetrics and Gynecology,
Zaporizhzhia State Medical and Pharmaceutical University

Serhienko Marina

MD, PhD. Associate Professor of the Department of Obstetrics and Gynecology
Zaporizhzhia State Medical and Pharmaceutical University

Demidenko Olexandr

MD, PhD. Head of the Department of Internal Diseases 2,
Zaporizhzhia State Medical and Pharmaceutical University

Shevchenko Anna

PhD. Assistant of the Department of Obstetrics and Gynecology
Zaporizhzhia State Medical and Pharmaceutical University

Kyryliuk Oleksandr

MD, PhD. Associate Professor of the Department of Obstetrics and Gynecology
Zaporizhzhia State Medical and Pharmaceutical University

Menopause should be considered as a risk factor for the development of cardiovascular diseases (CVD) that triggers a whole cascade of pathological changes in a woman's body, including the development of arterial hypertension, dyslipidemia, abdominal obesity, the emergence of insulin resistance, an increase in sympathoadrenal tone, endothelial function disorders, inflammatory vascular reactions [1]. Postmenopausal women have a higher risk of developing cardiovascular diseases, precisely because of estrogen deficiency and lipid metabolism disorders [2]. One of the problems associated with the onset of menopause is the loss of bone mass, which continues to increase in postmenopause. Osteoporosis affects from a third to a half of all women in the postmenopausal period [3]. The problem of osteoporosis in women is particularly relevant due to its high prevalence and serious consequences that lead to disability, a sharp deterioration in the life quality, and an increase in mortality [4].

In women, estrogen deficiency is one of the main causes of postmenopausal osteoporosis (OP) [5]. An insufficient level of estrogen at the beginning of the menopausal transition significantly contributes to changes in bone mass and its quality, playing a significant role in the development of postmenopausal OP [6]. The development of osteopenia and OP in menopausal women is associated with a change in the production of 1,25(OH)₂D₃, since estrogen deficiency causes a decrease in the synthesis of the active metabolite of vitamin D and decreases the absorption of calcium in the intestine, which causes secondary hyperparathyroidism [7, 8]. Non-pharmacological methods of prevention and lifestyle modification are recommended

for all postmenopausal women, regardless of their bone mineral density, the presence of clinical risk factors for fractures. General health and the proper state of bone tissue are supported by a balanced diet with sufficient intake of calcium and vitamin D, physical activity and avoidance of bad habits [9]. Calcium is the main element in bone tissue, a direct correlation between the use of calcium and an increase in bone mineral density (BMD) has been proven. It also enhances the antiresorptive effect of estrogens on bones.

The International Osteoporosis Foundation (IOF) recommends daily calcium intake for women [1, 9, 10]. It is recommended to consume calcium (1000-1200 mg/day), vitamin D (400-800 IU/day) and proteins (1.0-1.2 mg/kg body weight per day) for the effective prevention and treatment of postmenopausal OP and reducing the risk of osteoporotic fractures. For the treatment of postmenopausal OP, drugs with antiresorptive and anabolic effects on bone are used [11]. Oral bisphosphonates are often recommended for patients diagnosed with osteoporosis and an increased risk of fractures. However, for women with intolerance to oral bisphosphonates, hormone therapy during menopause may be an alternative. [6, 10]. Similar to statins, the effect of menopausal hormone therapy (MHT) on the development of atherosclerosis and CVD is thought to be time-dependent. Studies of symptomatic postmenopausal women have shown that up to 10 years of MHT use can have a significant beneficial effect on the risk of cardiovascular disease [6]. It should be emphasized that transdermal use of estrogen, which bypasses first-pass metabolism in the liver, has a lower risk of venous thromboembolism and stroke compared to oral administration [6, 12].

Menopause and the disorders caused by it are a risk factor for the development of both cardiovascular diseases and osteoporosis, which affects up to 50% of women. Estrogen deficiency is one of the main causes of postmenopausal osteoporosis in women. Therefore, regardless of the indicators of their bone mineral density, the presence of clinical risk factors for fractures, non-pharmacological methods of prevention, lifestyle modification, and the use of calcium and vitamin D preparations are recommended for all postmenopausal women. Menopausal hormone therapy, which should be prescribed taking into account contraindications, has a beneficial effect on both the risk of developing cardiovascular diseases and osteoporosis, given that the basis of this pathology is a decrease in the level of estrogen.

References

1. Barna O.M., Yefimenko O.O., Kosei N.V., Mishchenko L.A., Pedachenko N.Y., Tatarchuk T.F. Health care for women in menopause. Clinical lecture for general practitioners – family doctors. *Reproductive Endocrinology*. 2023;1(67):30-38.
2. Sobenin IA, Myasoedova VA, Orekhov AN. Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women. *Curr Pharm Des*. 2016;22(2):152-163.
3. Kondratiuk V. K., Gorban N. E., Dzis N. P., Kondatiuk K. O., Dzuba G. A. Women's health and osteoporosis: a modern view on the problem (Literature review) *Reproductive health of woman*. 2023;3(66):83-89.

4. Пірогова В.І. Менопауза і остеопороз. Роль гінеколога у вирішенні проблеми. За матеріалами конференції. Медичні аспекти здоров'я жінки. 2021;5-6(140-141):36-38.
5. Emmanuelle NE, Marie-Cécile V, Florence T, et al. Critical Role of Estrogens on Bone Homeostasis in Both Male and Female: From Physiology to Medical Implications. *Int J Mol Sci.* 2021;22(4):1568.
6. Na Z, Wei W, Xu Y, Li D, Yin B, Gu W. Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis. *Open Life Sci.* 2023;18(1):20220759.
7. Bouillon R, Marcocci C, Carmeliet G, et al. Skeletal and Extraskkeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. *Endocr Rev.* 2019;40(4):1109-1151.
8. Kondratiuk V. K., Gorban N. E., Dzis N. P., Kondatiuk K. O., Dzuba G. A. Women's health and osteoporosis: a modern view on the problem (Literature review) *Reproductive health of woman.* 2023;3(66):83-89.
9. Лікування остеопорозу у жінок у період постменопаузи. Експертна позиція Північноамериканського товариства з питань менопаузи (NAMS, 2021). *Медичні аспекти здоров'я жінки.* 2022;3-4.(144-145):24-32.
10. Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women [published correction appears in *Osteoporos Int.* 2020 Jan;31(1):209] [published correction appears in *Osteoporos Int.* 2020 Apr;31(4):801]. *Osteoporos Int.* 2019;30(1):3-44. doi:10.1007/s00198-018-4704-5.
11. Grygorieva N.V., V.M. Kovalenko, Korzh M.O., Tatarchuk T.F., Dedukh N.V., Strafun S.S., Dubossarska Z.M., Protsenko G.O., Kalashnikov A.V., Musiienko A.S., Regeda S.I. Efimenko O.O., Chaykivska E.F. Guideline for diagnostic, prevention and treatment of postmenopausal osteoporosis. *Pain, joints, spine.* 2023; 13, 3: doi:10.22141/pjs.13.3.2023.378
12. Crandall CJ, Hovey KM, Andrews C, et al. Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study. *Menopause.* 2017;24(10):1145-1153.